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Orally delivered DNA vaccines against duck enteritis virus (DEV) were developed using live attenuated Salmonella
typhimurium (SL7207) as a carrier and Escherichia coli heat labile enterotoxin B subunit (LTB) as a mucosal adjuvant.
DNA vaccine plasmids pVAX-UL24 and pVAX-LTB-UL24 were constructed and transformed into attenuated
Salmonella typhimurium SL7207 resulting SL7207 (pVAX-UL24) and SL7207 (pVAX-LTB-UL24) respectively. After
ducklings were orally inoculated with SL7207 (pVAX-UL24) or SL7207 (pVAX-LTB-UL24), the anti-DEV mucosal and
systemic immune responses were recorded. To identify the optimum dose that confers maximum protection, we
used different doses of the candidate vaccine SL7207 (pVAX-LTB-UL24) during oral immunization. The strongest
mucosal and systemic immune responses developed in the SL7207 (pVAX-LTB-UL24) (1011 CFU) immunized group.
Accordingly, oral immunization of ducklings with SL7207 (pVAX-LTB-UL24) showed superior efficacy of protection
(60-80%) against a lethal DEV challenge (1000 LD50), compared with the limited survival rate (40%) of ducklings
immunized with SL7207 (pVAX-UL24). Our study suggests that the SL7207 (pVAX-LTB-UL24) can be a candidate DEV
vaccine.Introduction
Duck viral enteritis (DVE, also called duck plague),
caused by Anatid herpesvirus 1 (Duck enteritis virus,
DEV), is an acute, contagious viral disease of ducks,
geese and swans, accounting for a high mortality rate in
ducks and decreased egg production, leading to heavy
economic losses [1–4]. The symptoms of this disease in-
clude vascular damage, eruptions at specific locations on
the mucosal surface of the gastrointestinal tract, lesions* Correspondence: cqrc_jry@163.com; chenganchun@vip.163.com
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reproduction in any medium, provided the orof lymphoid organs and degenerative sequelae in paren-
chymatous organs [5].
Immunization of ducks is an efficient way to prevent
DEV infection [6,7]. The commonly used DEV attenu-
ated live vaccine, provides a good protection against
DEV infection [8]. However, the production and supply
of the vaccine is insufficient, considering the large num-
ber of domestic and wild ducks [6]. Additionally, some-
times this vaccine fails to protect ducks after
intramuscular or subcutaneous vaccination and, because
it is grown in chick embryos, it may harbor other infec-
tious agents such as H5N1 [6,9]. Therefore, a novel and
more effective vaccine to protect against DEV infection
is urgently required. Recently, some enteropathogenic
bacteria [10] have been used as effective carriers for
DNA vaccine including attenuated strains of Listeria
monocytogenes [11], Salmonella spp [12] and ShigellaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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DNA vaccines to immunological inductive sites at muco-
sal surfaces and antigen-presenting cells (APC), which
can improve mucosal and systemic responses against
pathogens [14,15]. Amongst these bacteria, attenuated
Salmonella has been extensively studied [15,16]. How-
ever, the use of attenuated Salmonella typhimurium as a
DNA vaccine carrier in DEV has not yet been reported.
A few antigens derived from pathogenic microorgan-
isms, such as Escherichia coli heat-labile enterotoxin
(LT), can be used as adjuvants to improve systemic and
mucosal responses [17]. The nontoxic B subunit (LTB) is
commonly used for this purpose [18,19]. These strategies
of DNA vaccine combined with adjuvant might provide
new opportunities in the development of DEV vaccine.
DEV was classified as a separate genus of the Alpha-
herpesvirinae subfamily in the Herpesviridae family [1,2].
One gene UL24, is considered to be a core herpesvirus
gene and is conserved among most of the herpes viruses
[20,21], and null mutations or mutations in the con-
versed regions of UL24 can confer a syncytial phenotype
and result in decreased viral yields in cultured cells, indi-
cating that UL24 is important for efficient viralFigure 1 A schematic diagram of the construction of pVAX-UL24 and
pVAX-1 vector and a schematic diagram of LTB gene cloned into the recomreplication [22,23]. In addition, UL24 protein has the
ability to elicit a specific antibody response [24].
In this study, we used LTB as an adjuvant fused to
UL24 gene and the attenuated S. typhimurium aroA-
strain SL7207 as a vector to deliver DEV DNA vaccines.
The results indicate that oral immunization of the re-
combinant S. typhimurium could induce specific im-
mune response against DEV.
Materials and methods
Bacterial strains, plasmids, experimental ducklings
Eukaryotic expression pVAX1 (Invitrogen, Carlsbad,
California, USA), which contains the cytomegalovirus
(CMV) promoter and bovine growth hormone (BGH)
poly A signal, and enterotoxigenic E. coli K88ac were
generously provided by Professor Sanjie Cao of Sichuan
Agricultural University, China. The attenuated S. typhi-
murium aroA- strain SL7207 (S. typhimurium 2337–65
derivative hisG46, DEL407 [aroA::Tn10 (Tcs)]) was
kindly provided by Professor Kai Schulze of Helmholtz
Centre for Infection Research (Germany). 7-day-old
Tianfu ducklings were purchased from commercial duck
farms (Ya’an, China) and fed under standard conditions.pVAX-LTB-UL24. A schematic diagram of UL24 gene cloned into the
binant plasmid pVAX-UL24.
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E. coli K88ac genomic DNA was extracted using cetyl
trimethylammonium bromide (CTAB) [25]. According
to the DNA sequence of LTB published in GenBank
(Accession:EU113245.1), the primers were designed (p1:
5’- TTAAACTTAAGCTTATGAATAAAGTAAAATGT-
3’, p2: 5’-GAATTCGTTTTCCATACTGATTGC-3’) to
amplify the LTB gene containing a HindIII site (under-
lined) in primer 1 and an EcoRI site (underlined) in pri-
mer 2. The amplified DNA fragment of the LTB gene
was cloned into a pMD-T18 vector (TaKaRa, Dalian,
Shangdong, China) and sequenced. The 1230 bp UL24
gene fragment was cut from the pcDNA3.1 plasmid (lab
collection) by EcoRI and XhoІ digestion and inserted
into the pVAX1 expression vector, resulting in pVAX-
UL24 (Figure 1). Fragments of HindIII- and EcoRІ-
digested pMD-T18/LTB were inserted into the HindIII/
EcoRІ site of pVAX-UL24 (Figure 1). The recombinant
pVAX-UL24 and pVAX-LTB-UL24 were confirmed by
restriction enzyme digestion and sequencing.
Transient expression of the recombinant plasmids
When COS-7 cells growing in 6-well plates (Corning
Life Sciences, Corning, New York, USA) were 60-90%
confluent, the cells were transiently transfected with
plasmids pVAX-UL24, pVAX-LTB-UL24 and pVAX1
using Lipofectamine 2000 (Invitrogen), respectively.
Forty-eight hours after transfection, the cells were
washed with phosphate-buffered-saline (PBS) and were
fixed with 4% paraformaldehyde for 15 min at room
temperature and washed again. After being permeabi-
lized with 0.2% Triton X-100 (v/v in PBS) for 10 min,
the cells were blocked in 5% BSA for 1 h at 37 °C. Then,
the samples were incubated with diluted primary and
secondary antibodies at 37 °C for 1 h, respectively. Pri-
mary antibodies used were purified rabbit anti-DEV
UL24 polyclonal and secondary antibodies were fluores-
cein isothiocyanate (FITC)-conjugated goat anti-rabbit
IgG (Sigma, St. Louis, Missouri, USA). After the cell nu-
clei were counterstained with 4',6-diamidino-2-phenylin-
dole (DAPI) for 10 min at room temperature, the
coverslips were mounted onto glass slides with a drop of
buffered glycerol and analyzed by fluorescence micros-
copy (Nikon, Tokyo, Japan).
Transformation of attenuated S. typhimurium strain
SL7207 with DNA vaccine plasmids
The recombinant plasmids pVAX-UL24, pVAX-LTB-
UL24 and control vector pVAX1 were transformed into
attenuated S. typhimurium strain SL7207 by electropor-
ation using the Micropulser Electroporator (Bio-Rad,
Hercules, California, USA). The positive transformants
were selected on LB agar containing kanamycin (50 μg/
mL) and then were confirmed by sequencing and PCR.The constructs were named strain SL7207 (pVAX-
UL24), strain SL7207 (pVAX-LTB-UL24) and strain
SL7207 (pVAX1) respectively. The primers of UL24 gene
were designed as follows: primer 3: 5'-ATGGCATC-
GAAGGTACAGAAA AAGC-3' (forward) and primer 4:
5'-CTCGAGCTAGTGTTTAGTGGTCTGAA-3' (reverse).
The primers to amplify LTB-UL24 (about 1600 bp in
length) were primer 1 (as aforementioned) and primer 4.
RT-PCR detection of transcripts in vivo
2-week-old ducklings were orally administered
1 × 1010 CFU of SL7207 (pVAX-UL24) or SL7207
(pVAX-LTB-UL24), and control ducklings were given
the same dose of SL7207 (pVAX1). Three days after the
immunization, ileums (from three ducklings immunized
with SL7207 (pVAX-UL24), SL7207 (pVAX-LTB-UL24)
or SL7207 (pVAX1)) were removed and pooled. The
UL24 and LTB-UL24 transcripts (mRNA) were then ana-
lyzed by reverse transcriptase-polymerase chain reaction
(RT-PCR).
Immunization and serum sampling
Ducklings, randomly divided into 6 groups (40 per
group), were allowed to adapt to the new environment
for 7 days, deprived of food and water for 4 h prior to
immunization, and immunized three times at 7-day
intervals. For oral immunization, each duckling received
100 μL of 10% NaHCO3 intragastrically 30 min before
immunization to neutralize gastric acids. Ducklings of
group A, B and C were intragastrically inoculated with
SL7207 (pVAX-LTB-UL24) at doses of 1011, 1010 and
109 CFU per duckling respectively. Ducklings in groups
D and E were inoculated intragastrically with SL7207
(pVAX-UL24) and the control strain SL7207 (pVAX1),
respectively, at 1010 CFU per duckling. Group F duck-
lings received PBS and were used as a negative control.
At weeks 1, 2, 3, 4, 5, 6 and 8 after the first
immunization, three ducklings of each group were sacri-
ficed for sera, bile and duodenum. To prepare duodenal
fluid, its connective and fat tissues in serosa were
removed in PBS and were opened to expose their
lumens. After a 1 cm section of this intestinal tract was
placed in 1 mL of PBS containing 100 μg/mL of trypsin
inhibitor (Sigma), the mixture was centrifuged and the
supernatant was collected. Accordingly, the bile obtained
was centrifuged and the supernatant was collected. All
of these samples were stored at −20 °C prior to analysis.
Measurement of antibody levels
Enzyme-linked immunosorbent assay (ELISA) was used
to analyze DEV-specific antibodies in serum, duodenum
and bile. In brief, 96-well polystyrene microtitre plates
were coated with 100 μL 0.25 μg/mL purified DEV-
antigen and incubated overnight at 4 °C. The plates were
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20 (PBST) and blocked by incubation with 100 μL of
blocking solution (1% BSA in PBST) for 1 h at 37 °C.
After washing, a 100-μL volume of diluted duckling
serum was added to each well, and incubated for 1 h at
37 °C. Rabbit anti-duck IgG or IgA-horseradish peroxid-
ase conjugate (Sigma) was used as the secondary anti-
body at 1:2000 dilutions and incubated for 1 h at 37 °C,
then washed again. The substrate, 3,3’,5,5’-tetramethy1
benzidine (TMB), added and incubated for 30 min at
37 °C. 50 μL of 2 mol/L H2SO4 was added to stop the
reaction, and then the optical density (OD) at 450 nm
was measured using an ELISA reader.
Measurement of neutralizing antibody responses
Serum samples were inactivated at 56 °C for 30 min and
diluted in serial twofold dilutions in MEM (GIBCO,
Grand Island, New York, USA). Each sample was mixed
with an equal volume containing 200 TCID50 of DEV
and incubated for 1 h at 37 °C. One-hundred microlitersFigure 2 Indirect immunofluorescence detection of the expression of
G show FITC staining; B, E and H show DAPI staining; C, F and I are the m
immunofluorescence result of COS-7 cells transfected with pVAX1; (D, E, F)
pVAX-UL24; (G, H, I) Indirect immunofluorescence result of COS-7 cells tranof the above serum-virus mixture was transferred to
duck embryo fibroblast monolayers on 96-well culture
plates (Corning Life Sciences) and incubated at 37 °C for
1 h. The mixture in each well was then replaced with
MEM containing 2% FCS (GIBCO). Cytopathic effects
were observed for 4 days and the end-point dilution of
each serum sample was calculated by the Reed-Muench
formula [26].
Detection of CD4+ and CD8+ T cells by flow cytometry
Peripheral blood lymphocytes (PBL) were isolated and
indirect staining of the cells was carried out as described
elsewhere [7]. Briefly, PBL were isolated from hepari-
nized blood samples, washed twice by PBS, and adjusted
to a final concentration of 5 × 105 cells per mL. Then
1:200 diluted anti-duck CD4 monoclonal antibody and
1:1000 diluted anti-duck CD8 monoclonal antibody
(AbD Serotec Ltd, Oxford, UK) were added into the
cells. After incubation for 30 min at 4 °C in the dark,
FITC-labeled goat anti-mouse IgG (AbD Serotec Ltd)pVAX-UL24 and pVAX-LTB-UL24 in COS-7 cells (× 200). A, D and
erged images of FITC and DAPI staining. (A, B, C) Indirect
Indirect immunofluorescence result of COS-7 cells transfected with
sfected with pVAX-LTB-UL24.
Figure 3 RT-PCR detection of the transcripts of UL24 and LTB-
UL24 genes in vivo. (A) Lane M, DL 100–2000 marker; lane 1,
ducklings were orally immunized with SL7207 (pVAX-UL24); lane 2,
control ducklings were orally immunized with SL7207 (pVAX1); (B)
lane 1, ducklings were orally immunized with SL7207 (pVAX-LTB-
UL24); lane 2, control ducklings were orally immunized with SL7207
(pVAX1); lane 3, DL 100–2000 marker.
Figure 4 Humoral immune responses to DEV measured by
ELISA. (A) Serum IgG responses to DEV. (B) Serum IgA responses to
DEV. Sera were obtained at different time points and assayed by
end-point dilution ELISA using DEV as the coating antigen. Numbers
on the y-axis represent the means of average OD450 ± standard
deviations (n= 3). Statistical significance was determined using a
student’s t-test.
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PBS and resuspended in 500 μL PBS, followed by flow
cytometric analysis. Viable lymphocytes were gated on
the basis of forward and side scatter characteristics, and
10 000 events were analyzed for positive staining with
FITC. Data analysis was carried out using BD FACSAria
software.
Protection studies
To assess the protection of DNA vaccines against DEV
in immunized ducklings, 10 ducklings from each group
were orally challenged with 1000 lethal doses, 50%
(LD50) of DEV at 6 weeks after primary immunization.
These ducklings were monitored daily for survival for
10 days after challenge.
Results
Construction and transient expression of pVAX-UL24 and
pVAX-LTB-UL24 in COS-7 cells
Indirect immunofluorescence experiments demonstrated
that specific fluorescent granules dispersed in the nu-
cleus and cytoplasm in the cells transfected with pVAX-
UL24 or pVAX-LTB-UL24 (Figure 2D-I), whereas no
fluorescence was detected in cells infected with plasmid
pVAX1 (Figure 2A-C), indicating that UL24 and LTB-
UL24 were expressed in COS-7 cells. The recombinant
plasmid pVAX-UL24 or pVAX-LTB-UL24 was success-
fully transformed into attenuated S. typhimurium and
analyzed by PCR and then sequenced (data not shown).
Transcripts of UL24 and LTB-UL24 genes in vivo
To test the expression of DEV DNA vaccines in vivo,
total cellular RNA of ilea was isolated at day 3 after
immunization, and then was analyzed by RT-PCR for
the transcripts of UL24 or LTB-UL24 gene. As shown in
Figure 3, a DNA fragment about 1230 bp was amplified
from the RNA of ducklings immunized with SL7207
(pVAX-UL24), and a fragment about 1600 bp was ampli-
fied from ducklings immunized with SL7207 (pVAX-
LTB-UL24). However, there were no DNA fragments
amplified from RNA of control ducklings immunized
with SL7207 (pVAX1). These data showed that UL24
and LTB-UL24 were transcribed from DNA to mRNA
and therefore may be capable of expressing UL24 or
LTB-UL24 in duckling cells in vivo.
Humoral immune responses of ducklings
No clinical signs of disease and no animal died post
immunization during the entire experimental period. As
indicated in Figure 4, the pattern of serum IgA
responses was similar with that of the IgG responses.
From 1w to 5w post-immunization, they showed an up-
ward trend, peaked at week 5 and gradually decreased
after that. Ducklings in vaccine treated groups showedconsiderably enhanced antibody levels at week 5–6 post-
immunization, and statistically significant differences be-
tween these groups and the control groups (P< 0.05)
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in SL7207 (pVAX-LTB-UL24) (1011 CFU) immunized
group were 0.472 (Figure 4A) and 1.754 (Figure 4B), re-
spectively, at 5 weeks post-immunization, which were
significantly higher than those in the control groups
(P< 0.05). Significantly higher levels (P< 0.01) of anti-
DEV IgG and IgA antibodies in the orally immunized
groups were observed, compared with the control groups
during the entire experiment (Figure 4A and B).
Amongst the oral groups, humoral immune responses
induced by 1010 CFU of SL7207 (pVAX-LTB-UL24) were
higher than those induced by 1010 CFU of SL7207
(pVAX-UL24), but the antibody levels among these
groups showed no difference in significance (P> 0.05). In
addition, antibody responses of ducklings inoculated with
1011 CFU of SL7207 (pVAX-LTB-UL24) were the highest
among all the vaccinated groups throughout the entire
experiment. In contrast, no specific anti-DEV antibodies
were detected in the control groups.
Mucosal antibody responses of ducklings
DEV-specific IgA antibodies in the duodenum and bile
were measured by ELISA. As shown in Figure 5, the
antibody titers generated in vaccine-immunized groups
gradually increased and were dramatically higher than
those in control groups (P< 0.01). At 6 week post-
immunization, mucosal IgA antibody titers in duodenumFigure 5 Mucosal immune responses to DEV measured by
ELISA. (A) Bile IgA responses to DEV. (B) Duodenum IgA responses
to DEV. Bile and duodenum were obtained at different time points
and assayed by end-point dilution ELISA using DEV as a coating
antigen. Numbers on the y-axis represent the means of average
OD450 ± standard deviations (n= 3). Statistical significance was
determined using a student’s t-test.and bile reached their peak levels with the OD450 values
of 0.383 (Figure 5B) and 0.623 (Figure 5B) respectively.
Moreover, ducklings in groups A, B and C showed
stronger mucosal immune responses than those in group
D, especially at week 6 post-vaccination, but no differ-
ence in significance (P> 0.05). The IgA antibody levels
of group A were the highest among all the vaccinated
groups, with OD450 values ranging from 0.282 to 0.623
in bile and from 0.144 to 0.383 in the duodenum (Figure 5).
Notably, the specific bile IgA levels from these groups
were significantly higher than those of the duodenum
(P< 0.01). No antibody induction was observed in the
control groups during the experiment.
Induction of DEV neutralizing antibodies
In SL7207 (pVAX-LTB-UL24) immunized groups, duck-
lings immunized with 1011 CFU SL7207 (pVAX-LTB-
UL24) had the highest levels of neutralizing antibody,
which indicated that titers of neutralizing antibody were
dose-dependent. Detectable titers of neutralizing activity
in sera were generated by 1010 CFU SL7207 (pVAX-
UL24), but they were significantly lower than the titers
generated by 1010 CFU SL7207 (pVAX-LTB-UL24) (P
< 0.01). Ducklings immunized with SL7207 (pVAX1)
generated considerably lower neutralizing antibody
titers, whereas those receiving PBS had no detectable
neutralizing antibody responses (Table 1).
Analysis of T lymphocytes in PBL
As shown in Figure 6, the total number of CD4+ and
CD8+ cells produced by oral immunization were dra-
matically higher when compared to the results of control
groups (P< 0.05) and peak levels were reached between
the 4th and 6th weeks.
The strongest induction of CD4+ and CD8+ T cells
was observed in the 1 × 1011 CFU SL7207 (pVAX-LTB-
UL24) vaccinated group at all time points. The CD4+
population of this group was significantly higher than
those in other oral groups at 6 weeks post immunizationTable 1 Neutralizing antibody titers in ducklings
immunized with DEV DNA vaccines
Weeks Vaccinated groups Control groups
post-immunization A B C D E F
1 1:141.57 1:98.89 1:79.25 1:35.50 - -
2 1:142.57 1:100.47 1:82.56 1:37.58 - -
3 1:142.60 1:102.75 1:83.41 1:38.10 - -
4 1:146.50 1:104.20 1:86.64 1:42.23 - -
5 1:149.60 1:110.40 1:89.13 1:44.70 1:3.16 -
6 1:148.49 1:108.14 1:89.13 1:44.67 1:3.55 -
8 1:146.80 1:106.00 1:87.40 1:42.64 1:3.27 -
Data represent mean neutralizing antibody titer from 3 serum samples.
-, no neutralizing antibody response was detected.
Figure 6 T lymphocytes in PBL following DEV UL24 DNA vaccination. 1, 2, 3, 4, 6, 8 weeks after vaccination, the isolated PBL were stained
with monoclonal antibodies against duck CD4 (A) and CD8 (B). The results presented are the mean of all specimens of each group. Statistical
significance was determined using a student’s t-test.
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number of CD8+ in 1× 1011 CFU SL7207 (pVAX-LTB-
UL24) group was slightly higher but showed no difference
in significance (P> 0.05) during the entire experiment.
The number of CD4+ and CD8+ T cells generated in
group B was greater than that in group D, but no signifi-
cant difference was observed (P> 0.05).
Protection of ducklings against DEV challenge
As shown in Figure 7, unvaccinated ducklings died
quickly from day 4 to 8 and time to death of these duck-
lings was faster than those of vaccinated ducklings, with
statistical significance (P< 0.05). The survival ratio (80%)
of ducklings immunized with SL7207 (pVAX-LTB-UL24)
at doses of 1011 was significantly greater than those of
ducklings immunized with other vaccines (P< 0.05).
Discussion
DEV has the ability to establish latent infections and an
asymptomatic carrier state in waterfowl, which further
reinforces the difficulties in the control and prevention
of the transmission of DEV [7,27], and may explain why
conventional DEV vaccines (inactivated and attenuated
DEV preparations) sometimes fail to protect ducks.
Therefore, it is urgent to develop a novel or moreeffective vaccine to control DEV. A DNA vaccine is con-
sidered a good choice as it has several advantages, in-
cluding the simplicity of manufacture, biological
stability, cost effectiveness, safety, ease of transport in
lyophilized form and the ability to act in the presence of
maternal immunity [28]. More importantly, DNA vac-
cines elicit both humoral and cell-mediated immunity
(CMI) stimulated by the presentation of peptide frag-
ments. They have the potential to immunize against a
broad range of pathogens, since eukaryotic expression
can improve protein folding and therefore enable
surface-exposed epitopes to be correctly presented and
enable the introduction of post-translational modifica-
tion [29–32]. These immune responses can be improved
by other strategies such as improvements in DNA deliv-
ery and the inclusion of adjuvant (either as a gene or co-
administered agent) [33]. The evidence supporting this
hypothesis comes from this study where we used LTB as
a molecular adjuvant and developed a new Salmonella-
based DNA vaccine delivery system. Ultimately, we
demonstrated that DNA vaccines delivered by attenuated
Salmonella expressing UL24 gene have a great ability to
elicit systemic and mucosal immune responses and LTB
from E. coli is a very useful adjuvant for DEV DNA
vaccines.
Figure 7 Numbers of ducklings surviving challenge with 1000
LD50 of DEV. Six weeks after primary immunization, ducklings (10
ducklings per group) were orally challenged with 1000 lethal doses,
50% (LD50) of DEV. Mortality was monitored for 10 days after DEV
challenge.
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(APC) by DNA vaccine is a potential means of priming
immune responses, targeting DNA to APC is likely to
increase DNA vaccine potency [34–36]. In this study, we
detected the transcripts of UL24 and LTB-UL24 genes
by RT-PCR in vivo, indicating that both SL7207 (pVAX-
UL24) and SL7207 (pVAX-LTB-UL24) can be expressed
by APC (Figure 2). Because of the low number of APC
present in muscle, delivery of DNA vaccine through
traditional administration (intramuscularly or subcuta-
neously) would result in poor immune responses [33,37];
while a large fraction of bacteria carrying DNA vaccine
are taken up by APC which express and present the
antigen after crossing the intestinal mucosal barrier [14].
Therefore we used the oral route to immunize the duck-
lings. In addition, some component of gram-negative
bacteria such as lipopolysaccharide (LPS) has been
shown to act as a potent adjuvant which can enhance
immune responses [38]. Moreover, attenuated strains of
Salmonella are attractive candidates for mucosal vaccine
vectors, because they elicit both mucosal and systemic
immune responses against carried antigens [39,40].
Therefore, attenuated S. typhimurium is not only a
promising vaccine carrier, but may also act as an adju-
vant to stimulate immune responses [37]. Accordingly,
the results in this work were consistent with the afore-
mentioned findings. Oral delivery of DEV DNA vaccineswas an efficient way of inoculation, achieving high neu-
tralizing antibody titers and ELISA antibodies (Table 1,
Figures 4 and 5). Cell-mediated immune responses were
significantly stimulated by DNA vaccines delivered by
attenuated S. typhimurium (Figure 6).
HSV-specific CD4+ and CD8+ T cells are protective in
animal models during HSV infection and the antigen-
specific CD4+ T cells support later expression of
antigen-specific CD8+ T cells [41,42]. In our tests, the
number of CD4+ and CD8+ T cells showed an obvious
rise in the early stage after immunization with DNA vac-
cines. A dramatic increase was seen in the CD4+ popu-
lation, while CD8+ rose to a lesser degree. The most
significant induction in CD4+ and CD8+ T cells was
observed in 1 × 1011 CFU SL7207 (pVAX-LTB-UL24)
immunized group at all time points, indicating that
SL7207 (pVAX-LTB-UL24) can induce strong cellular
immune responses. In addition, CD4+ T cells play im-
portant roles in modulating immune responses, up-
regulating the costimulatory molecules on APC cells and
enhancing their ability to process and present antigen
[43]. Therefore the CD4+ T cell response is a prerequis-
ite when using a potential vaccine. Our work also
demonstrated that DEV vaccines could provoke both
specific CD4+ and CD8+ T cell responses to prevent or
control infection.
The cholera toxin (CT) and heat-labile toxin (LT) from
E. coli are the most commonly used mucosal adjuvants
for immunization. Co-administration of CT or LT with
antigen can result in substantial enhancement of
antigen-specific secretory and systemic antibody
responses [19,44,45]. LTB is widely used as an effective
adjuvant to induce protective mucosal and systemic im-
mune responses since LTB exhibits low toxicity, which
was also demonstrated by our work (Table 1, Figures 4,
5 and 6). Amongst the oral groups, SL7207 (pVAX-LTB-
UL24) induced obviously better mucosal and systemic
immune responses, compared with SL7207 (pVAX-
UL24). When comparing the three different doses of
SL7207 (pVAX-LTB-UL24), we found that immunogen-
icity of the DEV DNA vaccine was dose-dependent, with
higher doses of SL7207 (pVAX-LTB-UL24) (e.g.
1 × 1010 CFU or 1 × 1011 CFU) inducing better immune
responses. Delivery of the DNA vaccine at a low dose
(109 CFU) induced systemic and mucosal immune
responses, which were enhanced by increasing the dose
of attenuated Salmonella. Moreover, ducklings immu-
nized with 1011 CFU of SL7207 (pVAX-LTB-UL24)
showed the highest anti-DEV mucosal and systemic im-
mune response throughout the experiment.
Challenge studies revealed that higher mucosal and
systemic immune responses were more protective
against DEV infection. These findings suggest that the
DEV DNA vaccine with the LTB gene fused to UL24
Yu et al. Veterinary Research 2012, 43:56 Page 9 of 10
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protective prophylactic responses against DEV challenge
and this DNA vaccine at a high dose (1011 CFU) showed
a superior protection, demonstrating that LTB is a po-
tential and effective adjuvant of the DEV DNA vaccine.
Taken together, our results indicate that oral
immunization with attenuated S. typhimurium as a
DNA vaccine carrier induces efficient systemic and mu-
cosal immune responses. We report here the first at-
tempt to develop oral DNA vaccines against DEV
infection and have shown that orally administered atte-
nuated S. typhimurium co-expressing UL24 and LTB
was able to protect ducklings against DEV infection.
Consequently, a DNA vaccine encoding the UL24 gene
of DEV and LTB gene of E. coli delivered by attenuated
S. typhimurium may be a promising DEV vaccine.
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